Clinical

Dataset Information

0

Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer


ABSTRACT: This is a two arm, 2-center, Phase II, study of 5-FU, irinotecan, bevacizumab (FOLFIRI-beva) and hydroxychloroquine (HCQ) in patients with previously untreated metastatic colorectal cancer (mCRC). Up to 155 patients will be screened for DTP-signature and up to 31 evaluable patients who are determined to be DTP-signature high will be treated with FOLFIRI-beva and HCQ. Patients will continue to receive treatments until evidence of disease progression, intolerable side effects, withdrawal of consent or death.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 58886 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2022-01-07 | GSE193157 | GEO
2022-10-13 | PXD034196 | Pride
2021-11-13 | GSE188603 | GEO
2022-07-01 | GSE198290 | GEO
2022-02-17 | PXD029648 | Pride
| 2081555 | ecrin-mdr-crc
| 2249147 | ecrin-mdr-crc
| PRJNA670179 | ENA
| 2095451 | ecrin-mdr-crc
2020-10-21 | GSE159678 | GEO